Evidence map›Paper›PMID 40139890›Full record

Trial reportJournal of the American College of Cardiology2025

Invasive vs Conservative Management of Patients With Chronic Total Occlusion: Results From the ISCHEMIA Trial.

Sripal Bangalore, G B John Mancini, Jonathan Leipsic, Mathew J Budoff, Yifan Xu, Rebecca Anthopolos, Emmanouil S Brilakis, Aeshita Dwivedi, John A Spertus, Phil G Jones and 19 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyComparative Study
In one paragraph

Trial report in Journal of the American College of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01471522 (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01471522 nacompletednot on this map

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

TypeinterventionalSponsorNYU Langone HealthRan2012 to 2023Enrolled5,179ConditionsCardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart DiseasesArmscardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Selecting the right patient for CTO-PCI: is ischaemia still the key?European heart journal. Imaging methods and practice · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Sripal BangaloreNew York University Grossman School of Medicine, New York, New York, USA. Electronic address: sripalbangalore@gmail.com.
G B John ManciniUniversity of British Columbia, Vancouver, British Columbia, Canada.
Jonathan LeipsicUniversity of British Columbia, Vancouver, British Columbia, Canada.
Mathew J BudoffLundquist Institute, Los Angeles, California, USA.
Yifan XuNew York University Grossman School of Medicine, New York, New York, USA.
Rebecca AnthopolosNew York University Grossman School of Medicine, New York, New York, USA.
Emmanouil S BrilakisMinneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
Aeshita DwivediDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA; Division of Cardiology, Lenox Hill Hospital, Northwell Health, New York, New York, USA.
John A SpertusUniversity of Missouri-Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Phil G JonesUniversity of Missouri-Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Yoon Joo ChoUniversity of Missouri-Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Daniel B MarkDuke Clinical Research Institute and Duke University, Durham, North Carolina, USA.
Cameron J HagueUniversity of British Columbia, Vancouver, British Columbia, Canada.
James K MinCleerly, New York, New York, USA.
Harmony R ReynoldsNew York University Grossman School of Medicine, New York, New York, USA.
Ahmed ElghamazNorthwick Park Hospital-Royal Brompton Hospital, London, United Kingdom.
Rajesh Goplan NairGovernment Medical College, Kerala, India.
Kreton MavromatisEmory University School of Medicine and Atlanta VA Healthcare System, Atlanta, Georgia, USA.
Gilbert GosselinMontreal Heart Institute, Montreal, Quebec, Canada.
Subhash BanerjeeUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA.
Hristo PejkovUniversity Clinic of Cardiology, Skopje, Macedonia.
Steven LindsayBradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom.
J Aaron GranthamUniversity of Missouri-Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
David O WilliamsBrigham and Women's Hospital, Boston, Massachusetts, USA.
Gregg W StoneThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sean M O'BrienDuke Clinical Research Institute and Duke University, Durham, North Carolina, USA.
Judith S HochmanNew York University Grossman School of Medicine, New York, New York, USA.
David J MaronDepartment of Medicine, Stanford University, Stanford, California, USA.
ISCHEMIA Research Group

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
Integrated Biostatistical Training for CVD ResearchT32HL079896 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Sean M O'Brien, Ana-Maria Staicu · 2006 to 2026
$4.1M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
NCATS NIH HHS UL1 TR001445NHLBI NIH HHS T32 HL079896NHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

backgroundRandomized trials of chronic total occlusion (CTO) revascularization vs medical therapy have yielded inconsistent results.

objectivesThe aim of this study was to evaluate outcomes with an initial invasive strategy (INV) vs an initial conservative strategy (CON) in patients with coronary computed tomographic angiography (CCTA)-determined CTO in the ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial.

methodsParticipants in ISCHEMIA who underwent CCTA evaluated for CTO by the core laboratory (3,113 of 5,179 randomized patients [60%]) were categorized into subgroups with (100% stenosis) and without (<100% stenosis) CTO. Primary analysis compared outcomes in those randomized to INV vs CON using an intention-to-treat approach. Secondary analyses compared outcomes using inverse probability weighting to model successful CTO revascularization (REV) in all INV participants vs CON participants.

resultsOf the 3,113 CCTA-evaluable participants, 1,470 had at least 1 CTO (752 INV and 718 CON). INV did not reduce cardiovascular (CV) death or myocardial infarction (MI) (5-year difference -3.5%; 95% CI: -7.8% to 0.8%) and resulted in more procedural MIs (2.5%; 95% CI: 1.0%-4.0%) but fewer spontaneous MIs (-6.3%; 95% CI: -9.7% to -3.2%) than CON. CTO REV modeled across INV had a high probability (>90%) of any lower CV death or MI, MI, spontaneous MI, unstable angina, and heart failure counterbalanced by a higher rate of procedural MI. CTO REV significantly improved angina-related quality of life (mean difference 4.6 points), Rose Dyspnea Scale score (rescaled) (mean difference 5.3 points), and EQ-5D visual analog scale score (4.6 points).

conclusionsIn the ISCHEMIA trial, the risks and benefits of INV compared with CON were similar among patients with and without CCTA-determined CTO (more frequent procedural MI, less frequent spontaneous MI, and significantly improved angina and dyspnea-related quality of life). In an observational comparison, successful CTO REV was associated with a high probability of lower CV death or MI (driven by lower MI) compared with CON. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).

Indexed as

Conservative TreatmentCoronary OcclusionMyocardial RevascularizationPercutaneous Coronary InterventionAgedChronic DiseaseComputed Tomography AngiographyCoronary AngiographyFemaleHumansMaleMiddle AgedQuality of LifeTreatment Outcomechronic total occlusionpercutaneous coronary interventionrevascularizationstentsurgery

Identifiers

PMID40139890
PMCPMC12284807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.